Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial Academic Article uri icon


MeSH Major

  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal
  • Atherectomy
  • Coronary Disease
  • Diabetic Angiopathies
  • Fibrinolytic Agents
  • Heparin
  • Immunoglobulin Fab Fragments
  • Myocardial Infarction
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex


  • Abciximab treatment in diabetic patients led to a reduction in the composite of death and myocardial infarction, which was at least as great as that seen in nondiabetic patients. However, target vessel revascularization was reduced in nondiabetic but not diabetic patients. This effect may be associated in part with lower doses of heparin. These differences may be related to differences in the platelet and coagulation systems between diabetics and nondiabetics, the greater extent of coronary artery disease in diabetics, or patient selection and management factors.

publication date

  • May 19, 1998



  • Academic Article



  • eng

PubMed ID

  • 9609084

Additional Document Info

start page

  • 1912

end page

  • 20


  • 97


  • 19